SCHEMBL3107709

SCHEMBL3107709

CCc1sc(-c2ccc(C(F)(F)F)cc2)cc1C(Oc1ccc(C(=O)O)cc1)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
GCG P01275 1/20 0.36
EPHX2 P34913 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
KMT2A Q03164 1/20 0.36
PPARD Q03181 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
LTA4H P09960 1/20 0.35
GIPR P48546 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
NR4A2 P43354 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109044 0.89 GCGR (0.55) GCGRGCGGIPR
SCHEMBL3107556 0.87 GCGR (0.42) GCGRSMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3111621 0.83 SMN1; SMN2 (0.40) GCGRSMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3091283 0.82 RCE1 (0.41) GCGRGCGEPHX2ADRB1ADRB3
SCHEMBL3099931 0.81 PPARD (0.41) GCGRSMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3101381 0.80 KMT2A (0.39) SMN1; SMN2NPC1HPGDRAB9AEPHX2
SCHEMBL3102067 0.80 KMT2A (0.39) GCGRSMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3104458 0.79 KMT2A (0.38) SMN1; SMN2NPC1HPGDRAB9AEPHX2
SCHEMBL3089767 0.78 SMN1; SMN2 (0.35) SMN1; SMN2NPC1HPGDRAB9AEPHX2
SCHEMBL3108936 0.78 KMT2A (0.40) SMN1; SMN2NPC1HPGDRAB9AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR GCGR 3/4885SMN1; SMN2 4692/4885NPC1 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.